First approved TA-TMA therapy faces EU rejection just months after U.S. launch — commercial ramp determines whether the orphan franchise justifies the valuation

Bull

The permanent J-code effective July 1, 2026 removes billing friction at transplant centers, and CMS NTAP approval in August 2026 with October 1 implementation meaningfully improves hospital economics, accelerating formulary additions and patient uptake. As the first and only FDA-approved therapy for TA-TMA with a 61-68% complete response rate, YARTEMLEA faces no approved U.S. competitor, and a deepening field force presence converts the large unmet-need patient population into durable revenue growth well ahead of the $87.9 million remaining debt balance.

Bear

The EU CHMP rejection signals unresolved evidentiary concerns—single-arm trial design, small sample size, and lack of randomized controlled data—that could also dampen U.S. payer confidence and formulary committee decisions, limiting net pricing realization. TA-TMA is an ultra-rare indication with a limited and episodic patient population, and if Q2-Q3 2026 sales do not show a clear ramp above Q1's $9.9 million, the burn rate against a $135 million cash position will raise going-concern concerns given the $70.8 million in 2029 notes still outstanding.